Follow our journey toward a better tomorrow for patients with rare diseases as well as their families, caregivers, and supporting healthcare teams.

December 6, 2023

Sentynl receives worldwide proprietary rights and rolling New Drug Application with U.S. FDA pertaining to CUTX-101 copper histidinate CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease; rolling submission of New Drug Application to FDA is ongoing and expected to be completed in 2024 Solana Beach, CA and Ahmedabad, India – December […]

Read Now

September 7, 2023

Risk of death was 5.1 times higher in untreated patients versus patients treated with NULIBRY Treatment also led to improvements in urinary biomarker levels and development outcomes NULIBRY is the first therapy to reduce the risk of mortality in patients with known or presumed MoCD Type A Solana Beach, CA – […]

Read Now

July 20, 2023

Sentynl celebrates one year as a founding member of BeginNGS™ and continues support to advance screening for 419 treatable, genetic disorders in newborns Solana Beach, CA – July 20, 2023 — Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced its continued support […]

Read Now

November 8, 2022

San Diego, CA and California, MD – Nov. 8, 2022 – Sentynl Therapeutics, Inc. (“Sentynl”) a US-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare disease, joins the global Menkes disease community including the Menkes Foundation (“Menkes Foundation”) in recognizing the month of November as Menkes Disease Awareness Month. In support […]

Read Now

September 20, 2022

– The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years.  – European Commission (EC) decision is based on the efficacy and safety data collected to date […]

Read Now

August 10, 2022

– NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years – NULIBRY received a positive opinion from the Committee for […]

Read Now

July 25, 2022

CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural history study  Under an accelerated assessment pathway, a decision by the European Commission (EC), which […]

Read Now

June 27, 2022

Solana Beach, CA – June 27, 2022 —Sentynl Therapeutics, Inc. (Sentynl), a U.S. based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced that NULIBRY (fosdenopterin) was honored with a 2022 Industry Innovation Award by the National […]

Read Now

April 25, 2022

Solana Beach, CA – April 25, 2022 — Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the continued availability of NULIBRY (fosdenopterin) for Injection and the launch of Sentynl Cares. NULIBRY […]

Read Now

March 21, 2022

Cyprium Therapeutics, a subsidiry of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease CUTX-101 has potential to be first FDA-approved treatment for Menkes disease; rolling submission of New Drug Application to FDA is ongoing and expected to be completed in mid-year 2022  New York, NY, and Solana Beach, […]

Read Now

March 8, 2022

Palo Alto and Solana Beach, CA – March 8, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known […]

Read Now

December 15, 2021

New York, NY, and Solana Beach, CA — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced the initiation of a rolling submission of a New Drug Application (“NDA”) to […]

Read Now

November 15, 2021

Solana Beach, CA, and California, MD/PRNewswire — Sentynl Therapeutics, Inc. (“Sentynl”), a US-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, joins the global Menkes disease community including the Menkes Foundation (“Menkes Foundation”) in recognizing the month of November as Menkes Disease Awareness Month. In support of the patients and […]

Read Now

October 8, 2021

New York, NY, and Solana Beach, CA — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced positive results from an efficacy and safety analysis of data […]

Read Now

February 24, 2021

New York, NY, and Solana Beach, CA — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, and Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based specialty pharmaceutical company owned by the Zydus Group, today announced the execution of an asset purchase agreement to commit development funding for and acquire Cyprium’s proprietary rights […]

Read Now